EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial f...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zhang, Zihe, Shi, Ruifeng, Liu, Minghui, Liu, Chao, Chen, Chen, Liu, Hongyu, Chen, Jun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716470/
https://ncbi.nlm.nih.gov/pubmed/33276757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07667-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller